The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

André J. Scheen

University of Liège

Division of Diabetes

Nutrition and Metabolic Disorders

Division of Clinical Pharmacology



Name/email consistency: high



  • University of Liège, Division of Diabetes, Nutrition and Metabolic Disorders, Division of Clinical Pharmacology, Belgium. 1999 - 2013
  • University of Liège, Department of Medicine, CHU Liège, Liège, Belgium. 1998 - 2010
  • Department of Medicine, the Academic Hospital of Liège, CHU Sart Tilman (B35), Liège, Belgium. 2008


  1. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Scheen, A.J. Expert. Opin. Drug. Metab. Toxicol (2013) [Pubmed]
  2. Efficacy and safety of Jentadueto® (linagliptin plus metformin). Scheen, A.J. Expert. Opin. Drug. Saf (2013) [Pubmed]
  3. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Scheen, A.J. Expert. Opin. Drug. Metab. Toxicol (2013) [Pubmed]
  4. Gliptin versus a sulphonylurea as add-on to metformin. Scheen, A.J., Paquot, N. Lancet (2012) [Pubmed]
  5. Outcomes and lessons from the PROactive study. Scheen, A.J. Diabetes Res. Clin. Pract. (2012) [Pubmed]
  6. Squatting test: a dynamic postural manoeuvre to study baroreflex sensitivity. Scheen, A.J., Philips, J.C. Clin. Auton. Res. (2012) [Pubmed]
  7. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Scheen, A.J. Expert. Opin. Drug. Metab. Toxicol (2011) [Pubmed]
  8. Sibutramine on cardiovascular outcome. Scheen, A.J. Diabetes. Care (2011) [Pubmed]
  9. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Scheen, A.J. Clin. Pharmacokinet (2010) [Pubmed]
  10. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Scheen, A.J. Diabetes. Obes. Metab (2010) [Pubmed]
  11. Cardiovascular risk-benefit profile of sibutramine. Scheen, A.J. Am. J. Cardiovasc. Drugs (2010) [Pubmed]
  12. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Scheen, A.J., Charpentier, G., Ostgren, C.J., Hellqvist, A., Gause-Nilsson, I. Diabetes Metab. Res. Rev. (2010) [Pubmed]
  13. Controversy about the cardiovascular safety of sibutramine. Scheen, A.J. Drug. Saf (2010) [Pubmed]
  14. Addition of incretin therapy to metformin in type 2 diabetes. Scheen, A.J., Radermecker, R.P. Lancet (2010) [Pubmed]
  15. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Scheen, A.J. Expert. Opin. Drug. Metab. Toxicol (2010) [Pubmed]
  16. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Scheen, A.J., Paquot, N. Best Pract. Res. Clin. Endocrinol. Metab. (2009) [Pubmed]
  17. Voglibose for prevention of type 2 diabetes mellitus. Scheen, A.J. Lancet (2009) [Pubmed]
  18. The endocannabinoid system: a promising target for the management of type 2 diabetes. Scheen, A.J. Curr. Protein Pept. Sci. (2009) [Pubmed]
  19. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Scheen, A.J., Tan, M.H., Betteridge, D.J., Birkeland, K., Schmitz, O., Charbonnel, B. Diabet. Med. (2009) [Pubmed]
  20. Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Scheen, A.J., De Flines, J., De Roover, A., Paquot, N. Diabetes Metab. (2009) [Pubmed]
  21. Medications in the kidney. Scheen, A.J. Acta. Clin. Belg (2008) [Pubmed]
  22. Inhibitors of cannabinoid receptors and glucose metabolism. Scheen, A.J., Paquot, N. Curr. Opin. Clin. Nutr. Metab. Care (2008) [Pubmed]
  23. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. Scheen, A.J. J. Neuroendocrinol. (2008) [Pubmed]
  24. Exenatide once weekly in type 2 diabetes. Scheen, A.J. Lancet (2008) [Pubmed]
  25. New therapeutic approaches in type 2 diabetes. Scheen, A.J. Acta. Clin. Belg (2008) [Pubmed]
  26. Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?. Scheen, A.J. Nature Clinical Practice. Endocrinology & Metabolism (2008) [Pubmed]
  27. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Scheen, A.J. Diabetes Metab. (2007) [Pubmed]
  28. Abnormal glucose metabolism in patients treated with antipsychotics. Scheen, A.J., De Hert, M.A. Diabetes Metab. (2007) [Pubmed]
  29. Pharmacokinetic interactions with thiazolidinediones. Scheen, A.J. Clin. Pharmacokinet (2007) [Pubmed]
  30. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Scheen, A.J. Clin. Pharmacokinet (2007) [Pubmed]
  31. Does the metabolic syndrome help to select patients requiring high statin dose?. Scheen, A.J. Lancet (2006) [Pubmed]
  32. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F. Lancet (2006) [Pubmed]
  33. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Scheen, A.J. Drug. Saf (2005) [Pubmed]
  34. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?. Scheen, A.J. Diabetes Metab. (2005) [Pubmed]
  35. Pathophysiology of insulin secretion. Scheen, A.J. Ann. Endocrinol. (Paris) (2004) [Pubmed]
  36. Management of the metabolic syndrome. Scheen, A.J. Minerva Endocrinol. (2004) [Pubmed]
  37. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Scheen, A.J. Drugs (2004) [Pubmed]
  38. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Scheen, A.J. Diabetes Metab. (2004) [Pubmed]
  39. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Scheen, A.J. Diabetes Metab. (2004) [Pubmed]
  40. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Scheen, A.J. Drugs (2003) [Pubmed]
  41. Current management strategies for coexisting diabetes mellitus and obesity. Scheen, A.J. Drugs (2003) [Pubmed]
  42. Treatment of type 2 diabetes. Scheen, A.J. Acta. Clin. Belg (2003) [Pubmed]
  43. Pathophysiology of type 2 diabetes. Scheen, A.J. Acta. Clin. Belg (2003) [Pubmed]
  44. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Scheen, A.J., Ernest, P. Diabetes Metab. (2002) [Pubmed]
  45. Thiazolidinediones and liver toxicity. Scheen, A.J. Diabetes Metab. (2001) [Pubmed]
  46. Hepatotoxicity with thiazolidinediones: is it a class effect?. Scheen, A.J. Drug. Saf (2001) [Pubmed]
  47. Antiobesity pharmacotherapy in the management of type 2 diabetes. Scheen, A.J., Lefèbvre, P.J. Diabetes Metab. Res. Rev. (2000) [Pubmed]
  48. From obesity to diabetes: why, when and who?. Scheen, A.J. Acta. Clin. Belg (2000) [Pubmed]
  49. Severe/extreme obesity: a medical disease requiring a surgical treatment?. Scheen, A.J., Luyckx, F.H., Desaive, C., Lefèbvre, P.J. Acta. Clin. Belg (1999) [Pubmed]
  50. Oral antidiabetic agents. A guide to selection. Scheen, A.J., Lefèbvre, P.J. Drugs (1998) [Pubmed]
WikiGenes - Universities